These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 33871698)

  • 1. Improved outcomes associated with maximal extent of resection for butterfly glioblastoma: insights from institutional and national data.
    Boaro A; Kavouridis VK; Siddi F; Mezzalira E; Harary M; Iorgulescu JB; Reardon DA; Smith TR
    Acta Neurochir (Wien); 2021 Jul; 163(7):1883-1894. PubMed ID: 33871698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surgery for Glioblastoma in Light of Molecular Markers: Impact of Resection and MGMT Promoter Methylation in Newly Diagnosed IDH-1 Wild-Type Glioblastomas.
    Gessler F; Bernstock JD; Braczynski A; Lescher S; Baumgarten P; Harter PN; Mittelbronn M; Wu T; Seifert V; Senft C
    Neurosurgery; 2019 Jan; 84(1):190-197. PubMed ID: 29617848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surgical Resection of Anterior and Posterior Butterfly Glioblastoma.
    Opoku-Darko M; Amuah JE; Kelly JJP
    World Neurosurg; 2018 Feb; 110():e612-e620. PubMed ID: 29162526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of MGMT methylation and IDH-1 mutation on long-term outcome for glioblastoma treated with chemoradiotherapy.
    Millward CP; Brodbelt AR; Haylock B; Zakaria R; Baborie A; Crooks D; Husband D; Shenoy A; Wong H; Jenkinson MD
    Acta Neurochir (Wien); 2016 Oct; 158(10):1943-53. PubMed ID: 27526690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and outcomes of resection of butterfly glioblastoma.
    Dayani F; Young JS; Bonte A; Chang EF; Theodosopoulos P; McDermott MW; Berger MS; Aghi MK
    Neurosurg Focus; 2018 Jun; 44(6):E4. PubMed ID: 29852771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extent of tumor removal and molecular markers in cerebral glioblastoma: a combined prognostic factors study in a surgical series of 105 patients.
    Salvati M; Pichierri A; Piccirilli M; Floriana Brunetto GM; D'Elia A; Artizzu S; Santoro F; Arcella A; Giangaspero F; Frati A; Simione L; Santoro A
    J Neurosurg; 2012 Aug; 117(2):204-11. PubMed ID: 22655594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is MGMT promoter methylation to be considered in the decision making for recurrent surgery in glioblastoma patients?
    Pala A; Schmitz AL; Knoll A; Schneider M; Hlavac M; König R; Wirtz CR; Coburger J
    Clin Neurol Neurosurg; 2018 Apr; 167():6-10. PubMed ID: 29425743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic and predictive impact of MGMT promoter methylation in grade 3 gliomas.
    Haque W; Thong E; Andrabi S; Verma V; Brian Butler E; Teh BS
    J Clin Neurosci; 2021 Mar; 85():115-121. PubMed ID: 33581781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The utilization of MGMT promoter methylation testing in United States hospitals for glioblastoma and its impact on prognosis.
    Lee A; Youssef I; Osborn VW; Safdieh J; Becker DJ; Schreiber D
    J Clin Neurosci; 2018 May; 51():85-90. PubMed ID: 29483008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patterns of care and outcomes of chemoradiation versus radiation alone for MGMT promoter unmethylated glioblastoma.
    Lee A; Malakhov N; Sheth N; Wang A; Han P; Schreiber D
    Clin Neurol Neurosurg; 2018 Jul; 170():127-131. PubMed ID: 29777945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
    Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
    Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The butterfly effect on glioblastoma: is volumetric extent of resection more effective than biopsy for these tumors?
    Chaichana KL; Jusue-Torres I; Lemos AM; Gokaslan A; Cabrera-Aldana EE; Ashary A; Olivi A; Quinones-Hinojosa A
    J Neurooncol; 2014 Dec; 120(3):625-34. PubMed ID: 25193022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MGMT-Positive vs MGMT-Negative Patients With Glioblastoma: Identification of Prognostic Factors and Resection Threshold.
    Katsigiannis S; Grau S; Krischek B; Er K; Pintea B; Goldbrunner R; Stavrinou P
    Neurosurgery; 2021 Mar; 88(4):E323-E329. PubMed ID: 33432978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma.
    Rivera AL; Pelloski CE; Gilbert MR; Colman H; De La Cruz C; Sulman EP; Bekele BN; Aldape KD
    Neuro Oncol; 2010 Feb; 12(2):116-21. PubMed ID: 20150378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of MGMT promoter methylation and TP53 mutation in glioblastomas depends on IDH1 mutation.
    Wang K; Wang YY; Ma J; Wang JF; Li SW; Jiang T; Dai JP
    Asian Pac J Cancer Prev; 2014; 15(24):10893-8. PubMed ID: 25605197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy.
    Iaccarino C; Orlandi E; Ruggeri F; Nicoli D; Torricelli F; Maggi M; Cerasti D; Pisanello A; Pedrazzi G; Froio E; Crafa P; D'Abbiero N; Michiara M; Ghadirpour R; Servadei F
    Clin Neurol Neurosurg; 2015 May; 132():1-8. PubMed ID: 25723791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Craniotomy for recurrent glioblastoma: Is it justified? A comparative cohort study with outcomes over 10 years.
    Mukherjee S; Wood J; Liaquat I; Stapleton SR; Martin AJ
    Clin Neurol Neurosurg; 2020 Jan; 188():105568. PubMed ID: 31739155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MGMT inactivation and clinical response in newly diagnosed GBM patients treated with Gliadel.
    Grossman R; Burger P; Soudry E; Tyler B; Chaichana KL; Weingart J; Olivi A; Gallia GL; Sidransky D; Quiñones-Hinojosa A; Ye X; Brem H
    J Clin Neurosci; 2015 Dec; 22(12):1938-42. PubMed ID: 26249244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy.
    Li H; Li J; Cheng G; Zhang J; Li X
    Clin Neurol Neurosurg; 2016 Dec; 151():31-36. PubMed ID: 27764705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study.
    Kim YS; Kim SH; Cho J; Kim JW; Chang JH; Kim DS; Lee KS; Suh CO
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):661-7. PubMed ID: 22414280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.